Korea Expands National Medical Insurance Coverage Of Tamiflu, Relenza To Fight Swine Flu
This article was originally published in PharmAsia News
Executive Summary
SEOUL - With global health authorities warning of the possibility of the swine flu blooming into a pandemic, Korea's Ministry for Health, Welfare and Family Affairs has begun to cover Roche's Tamiflu (oseltamivir) and GlaxoSmithKline's Relenza (zanamivir) under the National Medical Insurance System for those likely exposed to the swine flu
You may also be interested in...
Korea Signs Deals With Roche, GSK For More Tamiflu, Relenza
SEOUL - Alarmed by the rising number of people infected with the H1N1 virus in neighboring Japan, and in Korea, the South Korean government has signed contracts recently to secure more of Roche's Tamiflu (oseltamivir) and GlaxoSmithKline's Relenza (zanamivir)
Korea Signs Deals With Roche, GSK For More Tamiflu, Relenza
SEOUL - Alarmed by the rising number of people infected with the H1N1 virus in neighboring Japan, and in Korea, the South Korean government has signed contracts recently to secure more of Roche's Tamiflu (oseltamivir) and GlaxoSmithKline's Relenza (zanamivir)
Global Response To Swine Flu Unprecedented; Vaccine Makers Ready To Switch
HONG KONG - For the first time in history, the emergence and spread of a pandemic is being tracked globally and in real time. The result has been a coordinated global response from countries both affected and unaffected as well as participation from the private sector